2025-07-20 - Analysis Report
Okay, here's the analysis of Teladoc Health Inc (TDOC) based on the provided information, presented in English with numbers first, followed by analysis.

## Teladoc Health Inc (TDOC) Analysis

**Company Overview:** Teladoc Health Inc is a telehealth company that offers virtual healthcare services.

### 1. Performance vs. S&P 500 (VOO)

*   **TDOC Cumulative Return:** -64.72%
*   **VOO (S&P 500) Cumulative Return:** 97.80%
*   **Spread:** -162.5 (Max: 456.6, Min: -162.6, Relative Spread: 0.0)

**Analysis:**

*   TDOC has significantly underperformed the S&P 500 (VOO) over the observed period.
*   The cumulative return difference is a staggering -162.5%. This indicates a very large deviation.
*   The Relative Spread of 0.0 suggests that TDOC's performance is at the very bottom of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta   | Cap(B) |
|------------|--------|--------|--------|--------|--------|
| 2015-2017  | 76.0%  | 60.6%  | 50.0%  | -0.0   | 6.1    |
| 2016-2018  | 128.0% | 59.3%  | 110.0% | -0.0   | 8.7    |
| 2017-2019  | 176.0% | 59.3%  | 147.0% | 0.4    | 14.7   |
| 2018-2020  | 237.0% | 64.0%  | 217.0% | 0.1    | 35.1   |
| 2019-2021  | -83.0% | 64.0%  | -132.0% | 0.1    | 16.1   |
| 2020-2022  | -295.0% | 81.3%  | -297.0% | 0.0    | 4.2    |
| 2021-2023  | -488.0% | 81.3%  | -506.0% | -0.6   | 3.8    |
| 2022-2024  | -111.0% | 81.3%  | -137.0% | -0.8   | 1.6    |
| 2023-2025  | -35.0% | 72.9%  | -84.0%  | -0.8   | 1.4    |

**Analysis:**

*   **CAGR:**  Historically strong growth in earlier periods (2015-2020), but significant negative growth in recent years.
*   **MDD:** High Maximum Drawdown (MDD) values indicate significant risk and volatility.
*   **Alpha:**  Positive Alpha in earlier periods, but extremely negative Alpha in recent years, suggesting poor risk-adjusted performance.
*   **Beta:**  Beta values are generally low or negative, indicating that TDOC's price movements are not strongly correlated with the overall market.  The recent negative Beta values suggest the stock is moving in the opposite direction of the market.
*   **Cap(B):**  Market capitalization has decreased significantly in recent years.

### 2. Recent Stock Price Movements

*   **Current Price:** 8.05
*   **Previous Close:** 8.04
*   **Change:** 0.12 (Slight increase)
*   **5-day Moving Average:** 8.03
*   **20-day Moving Average:** 8.17
*   **60-day Moving Average:** 7.48

**Analysis:**

*   The stock price experienced a slight increase in the most recent trading session.
*   The 5-day moving average is below the 20-day moving average, which is below the 60-day moving average. This suggests a short-term upward trend, but it's still below the medium-term trend.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.34 (Low Risk)
*   **RSI:** 43.71 (Neutral - not oversold or overbought)
*   **PPO:** -1.02 (Slightly Bearish - below zero suggests the price may be bottoming)
*   **Hybrid Signal:** cash_70%_Sell 0.3% of holdings (5 shares - Caution - MRI:0.34) (Cash Ratio: 70% on 2025-07-18)
*   **Delta_Previous_Relative_Divergence:** -0.1 (Negative - short-term decline)
*   **Expected Return:** -9698.9% (Very Negative - expected underperformance vs. S&P 500)

**Analysis:**

*   **MRI:** The low MRI suggests that the stock is relatively stable compared to other stocks.
*   **RSI:** The RSI is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** The negative PPO suggests that the short-term moving average is below the long-term moving average, indicating a possible downward trend.
*   **Hybrid Signal:** Cautious signal, recommending a high cash position and slight selling of shares.
*   **Delta_Previous_Relative_Divergence:** A negative value suggests a recent decline relative to its historical spread with the S&P 500.
*   **Expected Return:** The extremely negative expected return suggests that, based on current conditions, long-term investment in TDOC is projected to significantly underperform the S&P 500.
*  **Change:** The slight price increase could reflect immediate market reaction to news or short-term trading.

### 4. Recent News & Significant Events

*   **2025-07-17:**  Teladoc Health Inc (TDOC) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-07-18:**  Analysts are discussing Teladoc Health Inc's (TDOC) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-07-19:**  Teladoc Health Inc (TDOC)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-07-20:**  Market experts highlight both risks and opportunities for Teladoc Health Inc (TDOC), advising investors to monitor recent news and company announcements.

**Analysis:**

*   Recent news suggests significant events and volatility surrounding TDOC.
*   Analysts are actively discussing the company's performance and outlook.
*   Investors should closely monitor news and company announcements for potential impacts.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출          |
|------------|-------|---------------|
| 2025-05-01 | -0.53 | 0.63 B$       |
| 2024-10-31 | -0.19 | 0.64 B$       |
| 2024-08-01 | -4.92 | 0.64 B$       |
| 2024-04-26 | -0.49 | 0.65 B$       |
| 2025-05-01 | -0.49 | 0.65 B$       |

**Analysis:**

*   TDOC has reported negative EPS (Earnings Per Share) in all recent quarters.
*   Revenue has been relatively stable, around $0.63B - $0.65B per quarter.
*   The large negative EPS in 2024-08-01 is a significant concern.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-03-31   | $0.63B  | 68.73%        |
| 2024-12-31   | $0.64B  | 70.50%        |
| 2024-09-30   | $0.64B  | 71.94%        |
| 2024-06-30   | $0.64B  | 70.73%        |
| 2024-03-31   | $0.65B  | 69.89%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2025-03-31   | $1.43B  | -6.52%    |
| 2024-12-31   | $1.49B  | -3.25%    |
| 2024-09-30   | $1.51B  | -2.21%    |
| 2024-06-30   | $1.50B  | -55.77%   |
| 2024-03-31   | $2.29B  | -3.58%    |

**Analysis:**

*   **Revenue:** Relatively stable revenue, indicating consistent sales.
*   **Profit Margin:**  High profit margins, suggesting that the company is efficient in controlling its costs of goods sold. However, this doesn't translate into overall profitability due to other expenses.
*   **Equity:** Equity has been decreasing, indicating potential financial strain.
*   **ROE:** Negative ROE (Return on Equity) indicates that the company is not generating profits from its shareholders' investments.  The large negative ROE in 2024-06-30 is a major red flag.

### 7. Overall Analysis & Summary

Based on the provided data, Teladoc Health Inc (TDOC) faces significant challenges:

*   **Underperformance:**  TDOC has severely underperformed the S&P 500, with a massive negative cumulative return difference.
*   **Financial Losses:** Negative EPS and ROE indicate consistent financial losses.
*   **Declining Equity:** Decreasing equity raises concerns about financial stability.
*   **Volatility & Risk:** High Maximum Drawdown (MDD) and recent news suggest high volatility and risk.
*   **Negative Outlook:**  The extremely negative expected return suggests a poor long-term investment outlook based on current conditions.
*   **Technicals:** Technical indicators provide a mixed picture, with a slight recent price increase but overall bearish signals.

**Recommendation:**  Given the significant underperformance, financial losses, high volatility, and negative outlook, investors should exercise extreme caution with TDOC. Close monitoring of news, earnings reports, and company announcements is crucial. Further research is needed to understand the underlying causes of the company's struggles and potential paths to recovery.
